Acumen Gross Profit from 2010 to 2024

ABOS Stock  USD 2.31  0.06  2.53%   
Acumen Pharmaceuticals Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Acumen Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals
 
Gross Profit  
First Reported
2010-12-31
Previous Quarter
-42.3 M
Current Value
-40.2 M
Quarterly Volatility
15 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 8.6 M, Interest Income of 8.6 M or Depreciation And Amortization of 58 K, as well as many indicators such as Price To Sales Ratio of 415, Dividend Yield of 0.0 or PTB Ratio of 0.73. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Acumen Pharmaceuticals Correlation against competitors.
For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

Latest Acumen Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Acumen Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Acumen Pharmaceuticals minus its cost of goods sold. It is profit before Acumen Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Acumen Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (32.36 M)10 Years Trend
Slightly volatile
   Gross Profit   
       Timeline  

Acumen Gross Profit Regression Statistics

Arithmetic Mean(4,292,057)
Geometric Mean1,465,607
Coefficient Of Variation(350.11)
Mean Deviation9,858,131
Median1,688,424
Standard Deviation15,026,812
Sample Variance225.8T
Range44M
R-Value(0.61)
Mean Square Error152.6T
R-Squared0.37
Significance0.02
Slope(2,050,394)
Total Sum of Squares3161.3T

Acumen Gross Profit History

2024-40.2 M
2023-42.3 M
2022-169 K
2021 -4000.0
20201.4 M

Other Fundumenentals of Acumen Pharmaceuticals

Acumen Pharmaceuticals Gross Profit component correlations

0.990.96-0.74-0.950.940.540.080.991.01.00.760.690.720.82-0.56
0.990.97-0.77-0.940.940.45-0.061.00.990.990.710.640.670.8-0.51
0.960.97-0.77-0.960.930.51-0.110.960.960.970.70.690.640.76-0.65
-0.74-0.77-0.770.65-0.850.020.18-0.74-0.78-0.79-0.16-0.12-0.09-0.50.09
-0.95-0.94-0.960.65-0.93-0.67-0.05-0.94-0.95-0.94-0.83-0.82-0.78-0.880.75
0.940.940.93-0.85-0.930.440.030.930.960.960.640.580.570.87-0.49
0.540.450.510.02-0.670.440.580.480.510.50.90.940.90.59-0.9
0.08-0.06-0.110.18-0.050.030.58-0.030.060.040.340.30.380.14-0.2
0.991.00.96-0.74-0.940.930.48-0.030.990.990.740.660.70.82-0.53
1.00.990.96-0.78-0.950.960.510.060.991.00.720.660.680.82-0.54
1.00.990.97-0.79-0.940.960.50.040.991.00.720.650.680.81-0.54
0.760.710.7-0.16-0.830.640.90.340.740.720.720.960.990.82-0.83
0.690.640.69-0.12-0.820.580.940.30.660.660.650.960.950.72-0.95
0.720.670.64-0.09-0.780.570.90.380.70.680.680.990.950.76-0.81
0.820.80.76-0.5-0.880.870.590.140.820.820.810.820.720.76-0.57
-0.56-0.51-0.650.090.75-0.49-0.9-0.2-0.53-0.54-0.54-0.83-0.95-0.81-0.57
Click cells to compare fundamentals

About Acumen Pharmaceuticals Financial Statements

Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Gross Profit-42.3 M-40.2 M
Gross Profit Margin 1.14  1.09 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.